Date: Mar 3rd, 2023 Your Name: Yanyi Tian

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
		Time frame: past	36 months
2	Grants or contracts from	XNone	

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name: Haize Ge

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	30 months

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name:Xiyun Bian

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	30 months

	any antity /if not indicated		\neg
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
	Noyunies of meerises		
4	Consulting fees	X None	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name: Yao Wang

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	30 months

in item #1 above). Royalties or licenses X_None X_None A_Consulting fees X_None Spakers bureaus, manuscript writing or educational events Royalties or licenses X_None X_None Support for expert testimony X_None X_None		any entity (if not indicated		
4 Consulting feesX_None		in item #1 above).		
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid	3	Royalties or licenses	XNone	
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid				
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	5		XNone	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Patricipation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid East None X_None				
Payment for expert testimony				
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None				
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None	6		xNone	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		testimony		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	7	Support for attending	V None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None	′			
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or Advisory Board				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid				
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10		XNone	
group, paid or unpaid				
		-		
11 Stock or stock options X_None				
	11	Stock or stock options	x_None	
42 2 1 6 1 4 7 1	12	D : 1 C : 1	V N	
	12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None	
13 Other financial or non- X_None	13	Other financial or non-	X None	
financial interests	13		XNOTIC	
		maneral interests		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name:Yuezhao Lai

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	X None	30 months

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name:Yunqi Wang

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	30 months

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name:Yanwen Bai

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	X None	30 months

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name: Xi Zhang

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
		Time frame: past	36 months
2	Grants or contracts from	XNone	

	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
	Canadain a face	V. Name
4	Consulting fees	XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	XNone
	testimony	
7	Support for attending	XNone
	meetings and/or travel	
	J ,	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
	Stock of Stock Options	
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
1		

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:Mar 3rd, 2023

Your Name: Jingman Xu

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	

	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
	Canada in a face	V. Navas	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	J ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	•		
	Safety Monitoring Board or		
	Safety Monitoring Board or Advisory Board		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role	XNone	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society,		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy		
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	XNone	
11	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	XNone	
11	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	XNone	
11	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	XNone	
11 12	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNoneXNoneXNone	

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Mar 3rd, 2023 Your Name: Wei Tian

Manuscript Title:FUNDC1: A key mediator of adenosine A2BR activation-induced inhibition of cardiac mitophagy under

I/R conditions.

Manuscript number (if known):CDT-22-468

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding Time frame: past	This work was supported by grant 81700324 from the National Natural Science Foundation of China, grant 226Z7711G from the Hebei provincial special fund for central guiding local science and technology development plan and grant C20220354 from Hebei provincial financial assistance for the introduction of overseas Researchers. And grant X2019173 from the NCST university student innovation project.
2	Grants or contracts from	XNone	

in item #1 above). Royalties or licenses X_None X_None Consulting fees X_None X_None X_None Support or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Royalties or licenses X_None X_None		any entity (if not indicated		
4 Consulting feesX_None		in item #1 above).		
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid	3	Royalties or licenses	XNone	
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid				
Fayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or advocacy group, paid or unpaid				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Lectures, presentations, speakers bureaus, manuscript writing or educational events X_None				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	5	Payment or honoraria for	XNone	
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Patricipation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid East None X_None				
Payment for expert testimony				
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None				
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None	6		xNone	
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		testimony		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	7	Support for attending	V None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None	′			
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Safety Monitoring Board or Advisory Board				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid				
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10	in other board, society, committee or advocacy	XNone	
group, paid or unpaid				
11 Stock or stock options X_None				
	11	Stock or stock options	x_None	
42 2 1 6 1 4 7 1	12	D	V N	
	12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None	
13 Other financial or non- X_None	13	Other financial or non-	X None	
-	13	financial interests	XNOTIC	

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		